Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 10227
Country/Region: Zambia
Year: 2014
Main Partner: Provincial Health Office - Western Province
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $1,995,872 Additional Pipeline Funding: $1,422,449

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

Western Province which is predominantly rural will by 2012 have a population of 906,379 (Central Statistical Office) and 211 health facilities. The challenging terrain, compounded by low population density, low staffing levels, and insufficient infrastructure make health service provision difficult. Provincial HIV prevalence is 15.3% (ZDHS 2007). Key HIV drivers are vertical transmission from mother to child, multiple and concurrent sexual partners, low and inconsistent condom use, low levels of male circumcision, mobility and migration.

Western Provincial Health Office (WPHO)’s overall goal is to prevent new HIV infections and improve quality of life for people living with HIV/AIDS/TB. Target populations will include those living in high HIV and TB burden areas, pregnant women, children, PLWHA, and MARP.

Using the base funds, WPHO will increase access to services by scaling up, integrating services, and supporting outreach activities. WPHO will ensure quality of services in all technical areas through capacity building, mentoring, and adherence to quality assurance.

WPHO will support HIV prevention through implementation of PMTCT, Male Circumcision, education on risk reduction focusing on key HIV drivers with linkages to quality CTC, ART, and TB services that will be supported by quality laboratory services and strategic information.

WPHO will strengthen early infant diagnosis (EID), retention of mother baby pairs, Provider Initiated Testing and Counseling using family approach, and prevention among PLWHA and collaborate with other partners for nutrition assessment, counseling and support (NACS).

WPHO will develop a monitoring and evaluation plan for tracking progress and ensure adherence to USG financial regulations.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $300,000
Care: TB/HIV (HVTB) $50,000
Care: Pediatric Care and Support (PDCS) $150,000
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Testing: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $1,245,872
Treatment: Pediatric Treatment (PDTX) $250,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
C2.1.D By Age: <15 2015 2,850
C2.1.D By Age: <15 2015 900
C2.1.D By Age: 15+ 2015 8,550
C2.1.D By Age: 15+ 2015 2,700
C2.1.D By Age/Sex: <15 Female 2015 1,368
C2.1.D By Age/Sex: <15 Female 2015 432
C2.1.D By Age/Sex: <15 Male 2015 4,104
C2.1.D By Age/Sex: <15 Male 2015 1,296
C2.1.D By Age/Sex: 15+ Female 2015 1,482
C2.1.D By Age/Sex: 15+ Female 2015 468
C2.1.D By Age/Sex: 15+ Male 2015 4,446
C2.1.D By Age/Sex: 15+ Male 2015 1,404
C2.1.D By Sex: Female 2015 2,850
C2.1.D By Sex: Female 2015 900
C2.1.D By Sex: Male 2015 8,550
C2.1.D By Sex: Male 2015 2,700
C2.1.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 11,400
C2.1.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 3,600
C2.1.D Sum of Age disaggregates 2015 11,400
C2.1.D Sum of Age disaggregates 2015 3,600
C2.1.D Sum of Age/Sex disaggregates 2015 11,400
C2.1.D Sum of Age/Sex disaggregates 2015 3,600
C2.1.D Sum of Sex disaggregates 2015 11,400
C2.1.D Sum of Sex disaggregates 2015 3,600
C2.1.D_NGI By Age: <15 2015 3,750
C2.1.D_NGI By Age: 15+ 2015 11,250
C2.1.D_NGI By Age/Sex: <15 Female 2015 1,800
C2.1.D_NGI By Age/Sex: <15 Male 2015 5,400
C2.1.D_NGI By Age/Sex: 15+ Female 2015 1,950
C2.1.D_NGI By Age/Sex: 15+ Male 2015 5,850
C2.1.D_NGI By Sex: Female 2015 3,750
C2.1.D_NGI By Sex: Male 2015 11,250
C2.1.D_NGI Number of HIV-positive individuals receiving a minimum of one clinical service 2015 15,000
C2.1.D_NGI Sum of Age disaggregates 2015 15,000
C2.1.D_NGI Sum of Age/Sex disaggregates 2015 15,000
C2.1.D_NGI Sum of Sex disaggregates 2015 15,000
C2.4.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 3,600
C2.4.D Number of HIV-positive patients who were screened for TB in HIV care or treatment setting 2015 3,600
CARE_CURR Age/sex: <1 Female 2015 359
CARE_CURR Age/sex: <1 Male 2015 331
CARE_CURR Age/sex: 1-4 Female 2015 359
CARE_CURR Age/sex: 1-4 Male 2015 331
CARE_CURR Age/sex: 10-14 Female 2015 718
CARE_CURR Age/sex: 10-14 Male 2015 662
CARE_CURR Age/sex: 15-19 Female 2015 1,435
CARE_CURR Age/sex: 15-19 Male 2015 2,245
CARE_CURR Age/sex: 20-24 Female 2015 1,794
CARE_CURR Age/sex: 20-24 Male 2015 2,576
CARE_CURR Age/sex: 25-49 Female 2015 1,794
CARE_CURR Age/sex: 25-49 Male 2015 1,656
CARE_CURR Age/sex: 5-9 Female 2015 359
CARE_CURR Age/sex: 5-9 Male 2015 331
CARE_CURR Age/sex: 50+ Female 2015 359
CARE_CURR Age/sex: 50+ Male 2015 331
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 2,714
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 2,576
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 5,382
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 4,968
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 15,640
CARE_CURR Sum of Age/Sex disaggregates 2015 15,640
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2015 15,640
CARE_NEW Age/sex: 1-4 Female 2015 567
CARE_NEW Age/sex: 1-4 Male 2015 378
CARE_NEW Age/sex: 10-14 Female 2015 1,215
CARE_NEW Age/sex: 10-14 Male 2015 810
CARE_NEW Age/sex: 15-19 Female 2015 1,134
CARE_NEW Age/sex: 15-19 Male 2015 756
CARE_NEW Age/sex: 20-24 Female 2015 1,701
CARE_NEW Age/sex: 20-24 Male 2015 2,134
CARE_NEW Age/sex: 25-49 Female 2015 1,984
CARE_NEW Age/sex: 25-49 Male 2015 2,323
CARE_NEW Age/sex: 5-9 Female 2015 1,215
CARE_NEW Age/sex: 5-9 Male 2015 810
CARE_NEW Age/sex: 50+ Female 2015 284
CARE_NEW Age/sex: 50+ Male 2015 189
CARE_NEW Aggregated Age/sex: <15 Female 2015 3,997
CARE_NEW Aggregated Age/sex: <15 Male 2015 1,998
CARE_NEW Aggregated Age/sex: 15+ Female 2015 5,103
CARE_NEW Aggregated Age/sex: 15+ Male 2015 4,402
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 15,500
CARE_NEW Sum of Age/sex disaggregates 2015 15,500
CARE_NEW Sum of Aggregated Age/sex disaggregates 2015 15,500
CARE_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 12
CARE_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services 2015 17
CARE_SITE By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 142
CARE_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services 2015 194
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 154
CARE_SITE Sum of Numerator Site Support Type disaggregates 2015 154
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 211
CARE_SITE_den Sum of Denominator Site Support Type disaggregates 2015 211
FN_THER Age: <1 2015 250
FN_THER Age: 1-4 2015 200
FN_THER Age: 15-17 2015 500
FN_THER Age: 5-14 2015 250
FN_THER Aggregated Age: <18 2015 1,200
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2015 1,200
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2015 12,027
FN_THER Sum of Age disaggregates 2015 1,200
FN_THER Sum of Aggregated Age disaggregates 2015 1,200
HTS_TST Age/sex: 1-4 Female 2015 5,216
HTS_TST Age/sex: 1-4 Female 2015 5,670
HTS_TST Age/sex: 1-4 Female 2015 454
HTS_TST Age/sex: 1-4 Male 2015 3,478
HTS_TST Age/sex: 1-4 Male 2015 3,780
HTS_TST Age/sex: 1-4 Male 2015 302
HTS_TST Age/sex: 10-14 Female 2015 11,178
HTS_TST Age/sex: 10-14 Female 2015 12,150
HTS_TST Age/sex: 10-14 Female 2015 972
HTS_TST Age/sex: 10-14 Male 2015 7,452
HTS_TST Age/sex: 10-14 Male 2015 8,100
HTS_TST Age/sex: 10-14 Male 2015 648
HTS_TST Age/sex: 15-19 Female 2015 10,433
HTS_TST Age/sex: 15-19 Female 2015 11,340
HTS_TST Age/sex: 15-19 Female 2015 907
HTS_TST Age/sex: 15-19 Male 2015 6,955
HTS_TST Age/sex: 15-19 Male 2015 7,560
HTS_TST Age/sex: 15-19 Male 2015 605
HTS_TST Age/sex: 20-24 Female 2015 15,649
HTS_TST Age/sex: 20-24 Female 2015 17,010
HTS_TST Age/sex: 20-24 Female 2015 1,361
HTS_TST Age/sex: 20-24 Male 2015 10,433
HTS_TST Age/sex: 20-24 Male 2015 11,340
HTS_TST Age/sex: 20-24 Male 2015 907
HTS_TST Age/sex: 25-49 Female 2015 18,257
HTS_TST Age/sex: 25-49 Female 2015 19,845
HTS_TST Age/sex: 25-49 Female 2015 1,588
HTS_TST Age/sex: 25-49 Male 2015 12,172
HTS_TST Age/sex: 25-49 Male 2015 13,230
HTS_TST Age/sex: 25-49 Male 2015 1,058
HTS_TST Age/sex: 5-9 Female 2015 11,178
HTS_TST Age/sex: 5-9 Female 2015 12,150
HTS_TST Age/sex: 5-9 Female 2015 972
HTS_TST Age/sex: 5-9 Male 2015 7,452
HTS_TST Age/sex: 5-9 Male 2015 8,100
HTS_TST Age/sex: 5-9 Male 2015 648
HTS_TST Age/sex: 50+ Female 2015 2,608
HTS_TST Age/sex: 50+ Female 2015 2,835
HTS_TST Age/sex: 50+ Female 2015 227
HTS_TST Age/sex: 50+ Male 2015 1,739
HTS_TST Age/sex: 50+ Male 2015 1,890
HTS_TST Age/sex: 50+ Male 2015 151
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 27,572
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 2,398
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 18,382
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 1,598
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 46,948
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 4,082
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 31,298
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 2,722
HTS_TST Aggregated Age/sex: <15 Female 2015 29,970
HTS_TST Aggregated Age/sex: <15 Male 2015 19,980
HTS_TST Aggregated Age/sex: 15+ Female 2015 51,030
HTS_TST Aggregated Age/sex: 15+ Male 2015 34,020
HTS_TST By Test Result: Negative 2015 111,780
HTS_TST By Test Result: Negative 2015 121,500
HTS_TST By Test Result: Negative 2015 9,720
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 124,200
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 135,000
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 10,800
HTS_TST Sum of Age/Sex disaggregates 2015 124,200
HTS_TST Sum of Age/Sex disaggregates 2015 135,000
HTS_TST Sum of Age/Sex disaggregates 2015 10,800
HTS_TST Sum of Aggregated Age/Sex <15 2015 45,954
HTS_TST Sum of Aggregated Age/Sex <15 2015 49,950
HTS_TST Sum of Aggregated Age/Sex <15 2015 3,996
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 78,246
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 85,050
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 6,804
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 124,200
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 135,000
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 10,800
HTS_TST Sum of Test Result disaggregates 2015 124,200
HTS_TST Sum of Test Result disaggregates 2015 135,000
HTS_TST Sum of Test Result disaggregates 2015 10,800
HTS_TST_POS By Test Result: Positive 2015 12,420
HTS_TST_POS By Test Result: Positive 2015 13,500
HTS_TST_POS By Test Result: Positive 2015 1,080
LAB_ACC By site support type: Direct Service Delivery (DSD) 2015 1
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 1
LAB_ACC Sum of Support Type disaggregates 2015 1
LAB_CAP By clinical laboratories 2015 10
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 10
LAB_CAP By site support type: Technical Assistance-only (TA) 2015 10
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 10
LAB_CAP Sum of Site Support Type disaggregates 2015 20
PMTCT_ARV Life-long ART (including Option B+) 2015 2,194
PMTCT_ARV Life-long ART (including Option B+) 2015 279
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 548
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 93
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 2,194
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 465
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 2,194
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 279
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 1,371
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 175
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 823
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 104
PMTCT_ARV Sum of New and Current disaggregates 2015 2,194
PMTCT_ARV Sum of New and Current disaggregates 2015 279
PMTCT_ARV Sum of Regimen Type disaggregates 2015 2,742
PMTCT_ARV Sum of Regimen Type disaggregates 2015 372
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 3,207
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 641
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 3,207
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 3,207
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 2,005
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 1,202
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 3,207
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 3,848
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 2,194
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 244
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 122
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 3,207
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 2,438
PMTCT_EID Sum of Infant Age disaggregates 2015 2,438
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 15
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 15
PMTCT_SITE By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 88
PMTCT_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 88
PMTCT_SITE Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 103
PMTCT_SITE Sum of Numerator Support Type disaggregates 2015 103
PMTCT_SITE Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 103
PMTCT_SITE_den Sum of Denominator Support Type disaggregates 2015 103
PMTCT_STAT By: Known positives at entry 2015 686
PMTCT_STAT By: Known positives at entry 2015 116
PMTCT_STAT By: Number of new positives identified 2015 2,057
PMTCT_STAT By: Number of new positives identified 2015 349
PMTCT_STAT Number of new ANC and L&D clients 2015 24,055
PMTCT_STAT Number of new ANC and L&D clients 2015 4,080
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 22,853
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 3,876
PMTCT_STAT Sum of Positives Status disaggregates 2015 2,743
PMTCT_STAT Sum of Positives Status disaggregates 2015 465
PMTCT_STAT_NGI By: Known positives at entry 2015 802
PMTCT_STAT_NGI By: Number of new positives identified 2015 2,406
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 28,135
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 26,728
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 3,208
PP_PREV Age/sex: 10-14 Female 2015 2,522
PP_PREV Age/sex: 10-14 Male 2015 2,328
PP_PREV Age/sex: 15-19 Female 2015 7,566
PP_PREV Age/sex: 15-19 Male 2015 6,984
PP_PREV Age/sex: 20-24 Female 2015 15,132
PP_PREV Age/sex: 20-24 Male 2015 13,968
PP_PREV Age/sex: 25-49 Female 2015 20,176
PP_PREV Age/sex: 25-49 Male 2015 18,624
PP_PREV Age/sex: 50+ Female 2015 5,044
PP_PREV Age/sex: 50+ Male 2015 4,656
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 97,000
PP_PREV Sum of Age/Sex disaggregates 2015 97,000
PP_PREV Total number of people in the target population 2015 975,282
SITE_SUPP By program area/support type: Care and Support Technical Assistance-only (TA) 2015 211
SITE_SUPP By program area/support type: General Population Prevention Technical Assistance-only (TA) 2015 211
SITE_SUPP By program area/support type: HTC Direct Service Delivery (DSD) 2015 3
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA) 2015 208
SITE_SUPP By program area/support type: Key Populations Prevention Technical Assistance-only (TA) 2015 1
SITE_SUPP By program area/support type: Lab Direct Service Delivery (DSD) 2015 3
SITE_SUPP By program area/support type: Lab Technical Assistance-only (TA) 2015 8
SITE_SUPP By program area/support type: PMTCT Direct Service Delivery (DSD) 2015 12
SITE_SUPP By program area/support type: PMTCT Technical Assistance-only (TA) 2015 99
SITE_SUPP By program area/support type: TB/HIV Direct Service Delivery (DSD) 2015 6
SITE_SUPP By program area/support type: TB/HIV Technical Assistance-only (TA) 2015 185
SITE_SUPP By program area/support type: Treatment Direct Service Delivery (DSD) 2015 15
SITE_SUPP By program area/support type: Treatment Technical Assistance-only (TA) 2015 16
SITE_SUPP By program area/support type: VMMC Direct Service Delivery (DSD) 2015 24
SITE_SUPP Number of unique sites supported by PEPFAR 2015 211
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units 2015 31
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 31
TB_ARTSITE Sum of Numerator Site Support Type disaggregates 2015 31
TB_ARTSITE The number of PEPFAR-supported TB basic management units 2015 31
TB_ARTSITE The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 31
TB_ARTSITE_den Sum of Denominator Site Support Type disaggregates 2015 31
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 1,000
TX_CURR Age/Sex: <1 Female 2015 16
TX_CURR Age/Sex: <1 Female 2015 2
TX_CURR Age/Sex: <1 Male 2015 12
TX_CURR Age/Sex: <1 Male 2015 1
TX_CURR Age/Sex: 1-4 Female 2015 55
TX_CURR Age/Sex: 1-4 Female 2015 6
TX_CURR Age/Sex: 1-4 Male 2015 42
TX_CURR Age/Sex: 1-4 Male 2015 5
TX_CURR Age/Sex: 15+ Female 2015 5,174
TX_CURR Age/Sex: 15+ Female 2015 575
TX_CURR Age/Sex: 15+ Male 2015 4,497
TX_CURR Age/Sex: 15+ Male 2015 500
TX_CURR Age/Sex: 5-14 Female 2015 518
TX_CURR Age/Sex: 5-14 Female 2015 58
TX_CURR Age/Sex: 5-14 Male 2015 510
TX_CURR Age/Sex: 5-14 Male 2015 57
TX_CURR Aggregated Age/Sex: <1 Female 2015 16
TX_CURR Aggregated Age/Sex: <1 Female 2015 2
TX_CURR Aggregated Age/Sex: <1 Male 2015 12
TX_CURR Aggregated Age/Sex: <1 Male 2015 1
TX_CURR Aggregated Age/Sex: <15 Female 2015 589
TX_CURR Aggregated Age/Sex: <15 Female 2015 66
TX_CURR Aggregated Age/Sex: <15 Male 2015 564
TX_CURR Aggregated Age/Sex: <15 Male 2015 63
TX_CURR Aggregated Age/Sex: 15+ Female 2015 5,174
TX_CURR Aggregated Age/Sex: 15+ Female 2015 575
TX_CURR Aggregated Age/Sex: 15+ Male 2015 4,497
TX_CURR Aggregated Age/Sex: 15+ Male 2015 500
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 10,824
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 1,204
TX_CURR Sum of age/sex disaggregates 2015 129
TX_CURR Sum of Age/Sex disaggregations 2015 1,153
TX_CURR Sum of Aggregated Age/Sex <15 2015 1,153
TX_CURR Sum of Aggregated Age/Sex <15 2015 129
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 9,671
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 1,075
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 10,824
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 1,204
TX_CURR_NGI Age/Sex: <1 Female 2015 18
TX_CURR_NGI Age/Sex: <1 Male 2015 13
TX_CURR_NGI Age/Sex: 1-4 Female 2015 61
TX_CURR_NGI Age/Sex: 1-4 Male 2015 46
TX_CURR_NGI Age/Sex: 15+ Female 2015 5,749
TX_CURR_NGI Age/Sex: 15+ Male 2015 4,997
TX_CURR_NGI Age/Sex: 5-14 Female 2015 576
TX_CURR_NGI Age/Sex: 5-14 Male 2015 566
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 18
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 13
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 655
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 625
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 5,749
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 4,997
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 12,026
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 12,026
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 1,280
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 10,746
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 12,026
TX_DIST Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District 2015 16
TX_DIST Total number of PEPFAR supported District Health Offices 2015 16
TX_NEW Aggregated Grouping by Age: <1 Male 2015 7
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 7
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 851
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 170
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 1,250
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 1,282
TX_NEW By Age/Sex: <1 Female 2015 7
TX_NEW By Age/Sex: <1 Male 2015 7
TX_NEW By Age/Sex: 1-4 Female 2015 370
TX_NEW By Age/Sex: 1-4 Male 2015 34
TX_NEW By Age/Sex: 10-14 Female 2015 104
TX_NEW By Age/Sex: 10-14 Male 2015 95
TX_NEW By Age/Sex: 15-19 Female 2015 385
TX_NEW By Age/Sex: 15-19 Male 2015 256
TX_NEW By Age/Sex: 20-24 Female 2015 1
TX_NEW By Age/Sex: 20-24 Male 2015 449
TX_NEW By Age/Sex: 25-49 Female 2015 769
TX_NEW By Age/Sex: 25-49 Male 2015 513
TX_NEW By Age/Sex: 5-9 Female 2015 370
TX_NEW By Age/Sex: 5-9 Male 2015 34
TX_NEW By Age/Sex: 50+ Female 2015 95
TX_NEW By Age/Sex: 50+ Male 2015 64
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 3,553
TX_NEW Pregnancy status 2015 192
TX_NEW Sum of Age/Sex disaggregates 2015 3,553
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 3,553
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 3,307
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 3,556
TX_SITE By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 3,307
TX_SITE By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites 2015 3,556
TX_SITE Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 3,307
TX_SITE Sum of Numerator Site Support Type disaggregates 2015 3,307
TX_SITE Total number of PEPFAR-supported ART sites 2015 3,556
TX_SITE_den Sum of Denominator Site Support Type disaggregates 2015 3,556
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2015 120
VMMC_CIRC By Age: <1 2015 200
VMMC_CIRC By Age: 1-9 2015 400
VMMC_CIRC By Age: 10-14 2015 400
VMMC_CIRC By Age: 15-19 2015 800
VMMC_CIRC By Age: 20-24 2015 1,000
VMMC_CIRC By Age: 25-49 2015 1,000
VMMC_CIRC By Age: 50+ 2015 200
VMMC_CIRC By circumcision technique: Surgical VMMC 2015 4,000
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2015 80
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 3,920
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 4,000
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 4,000
VMMC_CIRC Sum of age disaggregates 2015 4,000
VMMC_CIRC_NGI By Age: <1 2015 200
VMMC_CIRC_NGI By Age: 1-9 2015 400
VMMC_CIRC_NGI By Age: 10-14 2015 400
VMMC_CIRC_NGI By Age: 15-19 2015 800
VMMC_CIRC_NGI By Age: 20-24 2015 1,000
VMMC_CIRC_NGI By Age: 25-49 2015 1,000
VMMC_CIRC_NGI By Age: 50+ 2015 200
VMMC_CIRC_NGI By circumcision technique: Surgical VMMC 2015 4,000
VMMC_CIRC_NGI By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2015 80
VMMC_CIRC_NGI By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 3,920
VMMC_CIRC_NGI By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 4,000
VMMC_CIRC_NGI Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 4,000
VMMC_CIRC_NGI Sum of Age disaggregates 2015 4,000
Cross Cutting Budget Categories and Known Amounts Total: $1,475,670
Human Resources for Health $1,150,200
Food and Nutrition: Commodities $16,000
Renovation $69,470
Motor Vehicles: Purchased $240,000
Key Issues Identified in Mechanism
enumerations.Malaria (PMI)
Child Survival Activities
Mobile Populations
Safe Motherhood
Tuberculosis
Workplace Programs
Family Planning